Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro

September 26, 2022

https://www.globenewswire.com/news-release/2022/09/26/2522482/0/en/Celularity-Publishes-New-Data-in-Frontiers-in-Immunology-Demonstrating-Placental-derived-Natural-Killer-Cells-CYNK-Recognized-and-Eliminated-Influenza-A-Virus-IAV-infected-Cells-In.html

FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq:CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced publication of a study in Frontiers in Immunology describing the antiviral role of its placental-derived natural killer (NK) cells (CYNK) in IAV infections.

Read more at globenewswire.com

Related news for (CELU)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.